Jim Fortner

Jim Fortner

 

VP-Finance

Business Strategy

 

 

James “Jim” Fortner is the Interim Vice President for Finance at Georgia Institute of Technology. Jim has 27 years of experience in university financial and accounting administration, including 17 years of experience in grants management administration. In his current role, Jim provides management oversight and direction of the Offices of Bursar and Treasury Services, Controller, Grants and Contracts Accounting, and Enterprise Resource Planning. Major responsibilities include financial compliance, financial stewardship, financial reporting, cost analysis and the delivery of effective and efficient business processes. A metro-Atlanta native and life-long resident, Jim has been with Georgia Tech since 1997 and previously worked at Emory University. Jim holds a Bachelors of Business Administration degree from Georgia State University and an MBA degree from Kennesaw State University. He is also a Certified Financial Research Administrator (CFRA).

 

       
     

News

   
     
   
  • Jul 18

    Coda Building Open House

    Georgia Tech community is invited to attend an open house to learn more about the Coda building and the developing Georgia Tech Coda community.

  • Recyclosaurus Comes to Clough Commons

    Georgia Tech’s Office of Solid Waste Management and Recycling donated around 1,000 of the 10,000 bottles needed for the project.

  • As We Get Parched, Cognition Can Sputter, Dehydration Study Says

    Getting parched can fuzz attentiveness and make it harder to solve problems. Dehydration can easily put a dent in those and other cognitive functions, a new metadata analysis of multiple studies shows. Researchers at Georgia Tech are particularly interested in possible ramifications for people who toil in the heat around heavy equipment or military hardware.

  • Technique May Improve Lung Delivery of Bacteria-Killing Phage

    A new delivery system for bacteriophages—viruses that selectively attack harmful bacteria—could help give doctors a new way to battle lung infections that threaten older patients and people with cystic fibrosis.